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Abstract The diverse composition and structure of
extracellular matrix (ECM) interfaces encountered by
tumor cells at secondary tissue sites can influence meta-
static progression. Extensive in vitro and in vivo data has
confirmed that metastasizing tumor cells can adopt differ-
ent migratory modes in response to their microenviron-
ment. Here we present a model that uses human stromal
cell-derived matrices to demonstrate that plasticity in
tumor cell movement is controlled by the tumor-associated
collagen receptor Endo180 (CD280, CLEC13E,
KIAA0709, MRC2, TEM9, uPARAP) and the crosslinking
of collagen fibers by stromal-derived lysyl oxidase (LOX).
Human osteoblast-derived and fibroblast-derived ECM
supported a rounded ‘amoeboid-like’ mode of cell migra-
tion and enhanced Endo180 expression in three prostate
cancer cell lines (PC3, VCaP, DU145). Genetic silencing
of Endo180 reverted PC3 cells from their rounded mode of
migration towards a bipolar ‘mesenchymal-like’ mode of
migration and blocked their translocation on human
fibroblast-derived and osteoblast-derived matrices. The
concomitant decrease in PC3 cell migration and increase in
Endo180 expression induced by stromal LOX inhibition
indicates that the Endo180-dependent rounded mode of
prostate cancer cell migration requires ECM crosslinking.
In conclusion, this study introduces a realistic in vitro
model for the study of metastatic prostate cancer cell
plasticity and pinpoints the cooperation between tumor-
associated Endo180 and the stiff microenvironment
imposed by stromal-derived LOX as a potential target for
limiting metastatic progression in prostate cancer.
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Introduction
Metastatic bone disease (MBD) affects approximately 1
million advanced cancer patients per annum in the EU,
USA and Japan; and estimates suggest that approximately
one fifth of MBD cases result from advanced prostate
cancer [1]. MBD is normally accompanied by the presence
of additional metastatic lesions in visceral organs. How-
ever, in vitro experimental systems used to study putative
metastatic targets tend to overlook the precise composition,
organization and bioactivity of human bone and visceral
tissues. The de novo extracellular matrix (ECM) produced
by human trabecular bone osteoblasts is abundant in the
minerals, proteins and growth factors found in normal
human bone, which provides an accurate biomaterial to
study therapeutic targets in the context of MBD [2–4].
Likewise, human fibroblast-derived ECM has been used to
develop more realistic in vitro models of human cancer
localized in visceral tissue in which its influence on ther-
apeutic strategies can be considered [5, 6].
Tumor cells can adopt different modes of migration
during metastasis. Three modes of tumor cell migration
include grouped, bipolar and rounded, which respectively
involve: (a) collective ‘epithelioid-like’ cell clusters
directed by a leader cell; (b) ‘mesenchymal-like’ translo-
cation of single cells coordinated by forward protrusion
and rear retraction of the plasma membrane; and
(c) ‘amoeboid-like’ forward translocation of singular
spheroidal cells [7, 8]. Tumor cells can switch back-and-
forth between different modes of migration in response to
external and/or internal cues. This type of morphological
plasticity is a feature of the epithelial-to-mesenchymal,
mesenchymal-to-amoeboid and collective-to-amoeboid
transitions that occur during tumor progression [9, 10]. The
‘amoeboid-like’ cell phenotype predominates at the inva-
sive edge of high-grade tumors [11] and has been identified
as an escape mechanism from some anti-invasive strategies
[12]. Tumor cells engaged in this rounded mode of cell
migration do not require focal adhesion turnover as they do
for bipolar ‘mesenchymal-like’ migration [13]. Instead
rounded cell migration is driven by the spatial localization
of integrins and cytoskeletal regulators at the posterior
plasma membrane [14, 15] and generation of RhoA and
Rho kinase associated protein kinase (ROCK)-based acti-
nomyosin contractile signals [16].
The type I transmembrane collagen receptor Endo180
(CD280, CLEC13E, KIAA0709, MRC2, TEM9, uPARAP)
is as a strong prognostic indicator for prostate cancer sur-
vival [17, 18]. Within this context Endo180 functions as a
modulatory switch for epithelial-to-mesenchymal transition
(EMT), and pro-invasive behavior in normal prostate
epithelial cells triggered by increased crosslinking and
stiffness of the basement membrane following its exposure
to advanced glycation end-products (AGEs) [17, 18]. The
pro-migratory and pro-invasive role of Endo180 involving
the promotion of RhoA-ROCK-based actinomyosin con-
tractility at the cell posterior [17–19] has been confirmed in
a range of tumor and stromal cell types, both in vivo and
in vitro, using ectopic over expression, genetic silencing,
genetic ablation or targeted blockade of receptor function
[17–30]. Given the expression of Endo180 observed in
tumor cell foci in metastatic bone lesions [4], and increased
levels of soluble Endo180 in the serum of patients with
visceral and bone metastases [31], we hypothesized that
Endo180 can regulate prostate cancer cell plasticity on the
bone-like ECM derived from human osteoblasts and vis-
ceral tissue-like ECM derived from human fibroblasts.
Lysyl oxidase (LOX) is a copper-dependent amine
oxidase that is produced by osteoblasts and fibroblasts to
give tissue its structural support and mechanical stiffness
by crosslinking the adjacent collagen fibers that they
deposit as part of the ECM [32, 33]. LOX plays a funda-
mental role in metastasis [34–37], including the formation
of the pre-metastatic lesions in bone that are colonized by
circulating tumor cells and expand into occult osteolytic
metastases [38]. Considering the positive cooperation
between tumor-associated Endo180 and AGE-dependent
crosslinking and stiffness of basement membrane matrix
[18], we hypothesized that Endo180-dependent prostate
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cancer cell migration cooperates with LOX-dependent
crosslinking of the ECM derived from human osteoblasts
and fibroblasts.
Materials and methods
Cells and cell culture
For osteoblast isolation approximately fifty post-operative
human trabecular bone chips of 1–2 mm2 were washed
thoroughly in PBS to remove hematopoietic cells and
incubated for 2 h at 37 C in 10 ml of 1.2 mg/ml type IV
collagenase diluted in DMEM (Invitrogen Ltd. Paisley,
UK). Supernatants containing digested cellular components
([107 cells) were harvested and cultured at 37 C in 5 %
CO2 in a 1:1 mix of DMEM and F-12 medium (Invitrogen
Ltd.) supplemented with 10 % v/v FBS (First Link UK
Ltd., Birmingham, UK), 2 mM L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin and 0.25 mg/ml
amphotericin B (Invitrogen Ltd.). Primary human osteo-
blasts and HCA2-hTERT human fibroblasts were main-
tained in DMEM ?10 % v/v FCS, 1 mM penicillin/
streptomycin and 2 mM L-glutamine.
PC3, DU145 and VCAP cells were maintained in RPMI
medium (Invitrogen Ltd.) ?10 % v/v FBS, 1 mM peni-
cillin/streptomycin and 2 mM L-glutamine. Endo180
knockdown and control cells were generated by transfec-
tion (Qiagen Superfect) of PC3 cells with the shRNA
vector pRNATin-H1.2/Hygro containing coral GFP (Anti-
bodies-Online GmbH, Aachen, Germany) and shEndo180
or non-targeting shEndo180 scrambled control (shSCN)
sequence inserts [26, 39] that were evaluated previously to
rule out any off-target effects on other pro-migratory and
pro-invasive proteins [17, 19]. Transfected cells were
selected in fully supplemented DMEM containing hygro-
mycin-B (20 lg/ml) (Santa Cruz Biotechnology Inc.,
Heidelberg, Germany, UK). PC3 cells were transfected
with the pcDNA3-Endo180 or empty pcDNA3 vector using
lipofectamine and selected with G418 (0.5 mg/ml), as
previously described [26, 39].
Matrix preparation and analysis
Rat type I collagen derived from rat tails was commercially
sourced (#354236, BD Biosciences, Oxford, UK) and used
at a concentration of 50 lg/ml in 0.02 M glacial acetic acid
to coat wells following the manufacturers instructions. For
human cell-derived ECM production HCA2 fibroblasts and
primary human trabecular bone osteoblasts were seeded at
a density of 1.5 9 104 cells per well in 96-well plates
(#CLS3595, Corning Costar). Confluent cultures of
HCA2 fibroblasts were stimulated with 2 mM ascorbate to
induce the production of native ECM. Confluent cultures of
primary human trabecular bone osteoblasts were stimulated
with 100 lM ascorbate, 10 nM dexamethasone and 10 mM
b-glycerophosphate to induce mineralized ECM production
as previously described [2, 4]. Stimulation media were
replaced every 2 days. After 10 days cells were washed
with PBS (3 9 5 min) and removed by three successive
freeze–thaw cycles (in PBS) and incubation in 1 % w/v
sodium deoxycholate for 5 min. Resulting decellularized
matrices were washed with PBS (5 9 5 min) before use.
Mineralization was determined by von Kossa staining
(5 % w/v silver nitrate), as previously described [4].
BAPN (0.1–1.0 mM) was included in stimulation media
of fibroblasts and osteoblasts during the 10-day period of
matrix generation to inhibit LOX-dependent type I colla-
gen fiber crosslinking. After 10 days the matrices gener-
ated in the presence of BAPN were decellularized. The
inhibitory effect of BAPN on collagen crosslinking in
fibroblast-derived ECM and osteoblast-derived ECM was
ascertained by adapting a previously described method
[37]. In brief, decellularized ECM derived from fibroblasts
and osteoblasts (untreated or treated with BAPN) were
immunostained with rabbit anti-human type I collagen
polyclonal antibody (R1038X, Acris Antibodies GmbH,
Herford, Germany) and secondary anti-rabbit Alexa Fluor
488-conjugated IgG (Invitrogen Ltd.). Images of the type I
collagen fibers present in fibroblast-derived ECM and
osteoblast-derived ECM were acquired using Image
XpressMICRO (IXM) (Molecular Devices UK Ltd., Wok-
ingham UK) [4]. The curvature ratio (defined as x/y, where
x = the total length of each fiber and y = the linear dis-
tance between the start and end of each fiber) was calcu-
lated using Image J software (arbitrary units) in images of
type I collagen fibers. The same images were processed
using Metamorph software (Molecular Devices UK Ltd.)
to calculate integrated fluorescent signal intensity per unit
area (lm2) using a modification of a protocol used to cal-
culate the integrated fluorescent signal intensity of type I
collagen fibers per cell [4].
Cell morphology and migration assays
Cells were seeded at a density of 2 9 103 cells per well on
plastic, type I collagen, fibroblast-derived ECM and osteo-
blast-derived ECM in 96-well Optilux Black/Clear Bottom
plates (#734-0395, VWR International Ltd., Lutterworth,
UK) and allowed to adhere prior to image acquisition at a
rate of 1 frame every 30 min for 24 h using IXM set to live
cell imaging mode (5 % v/v CO2 at 37 C). Segmented
images were used to manually score the number of cells that
were undergoing ‘grouped’ versus ‘singular’ cell migration
at time zero (0 h) and at each 6-h time point of for the 24-h
experimental time frame. In the case of ‘singular’ cell
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migration cells were scored according to a bipolar versus
rounded mode of cell migration. The predominant mode of
cell migration was classified according to the criteria pre-
sented in Table 1. The % of cells with each phenotype was
then used to calculate the rounded/bipolar ratio at time zero
(0 h) and at each 6-h time point of the 24-h experimental
time frame. The average cell velocities (lm/h) were calcu-
lated from the cell trajectories generated from manual cell
tracking and post analysis (Metamorph software). For all
conditions tested the tracks from C100 cells were used to
calculate the average cell velocities.
Flow cytometry
Cells were trypsinized and fixed in 4 % w/v paraformalde-
hyde (10 min), blocked and permeabilized in immunofluo-
rescence buffer (IFB: 4 % w/v BSA and 1 % v/v FBS)
containing 0.2 % w/v saponin. Cells were pelleted and
incubated with anti-human Endo180 primary monoclonal
antibody (A5/158, E1/183 or 39.10) diluted in IFB (1 h),
washed in IFB (3 9 5 min), incubated with Alexa Fluor-
555 conjugated secondary antibody diluted in IFB (1 h) and
washed IFB (3 9 5 min). Cells were pelleted, resuspended
in PBS and assessed by flow cytometry (BD FACS Canto,
BD, Oxford, UK). Gating was performed with unstained
cells and cells stained with isotype matched IgG.
Immunoblot analysis
Protein concentrations in whole cell lysates were deter-
mined using a Pierce BCA protein assay kit. Equal amounts
of protein were resolved by SDS-PAGE using 7 % w/v
polyacrylamide gels and electroblotted onto PVDF mem-
branes, which were incubated at room temperature in
blocking buffer (PBS ? 5 % w/v BSA) (1 h) then primary
antibody (anti-Endo180 A5/158 mAb; anti-GAPDH) dilu-
ted in blocking buffer at 4 C (16 h). After washes in
PBS? 0.1 % v/v Tween-20 (PBS-T) (5 9 5 min) blots
were incubated in HRP-conjugated goat anti-mouse or goat
anti-rabbit IgG diluted in blocking buffer (1 h). Blots were
washed in PBS-T (5 9 5 min) prior to visualization of
immunoreactive bands using chemiluminescence.
Cell adhesion assay
Cell adhesion could not be measured using crystal violet
because the fibroblast-derived and osteoblast-derived ECM
retained the stain. Instead, cells were seeded at a density of
1.5 9 104 per well of a 96-well plate onto test substrata
and incubated for 1 h before washing in PBS and addition
of culture medium containing CellTiter-Glo buffer (Pro-
mega, UK) at a ratio of 1:1 and final volume of 200 ll.
Plates were mixed vigorously for 2 min to induce cell lysis
and the contents of each well transferred to opaque 96-well
plates (Corning Costar; Z37 185-8; Sigma Aldrich Ltd.,
Poole, UK). Luminescence was measured on a PHERAs-
tarPlus plate reader (BMG LabTech, Aylesbury, UK).
MTT cell proliferation assay
1.2 9 104 cells per well were seeded onto test substrata in
24-well plates and incubated for 48 h. 5 mg/ml MTT was
added and cells incubated for 3.5 h at 37 C. Media was
removed and 300 ll of extraction buffer (0.5 M
dimethylformamide; 20 % w/v SDS) added per well fol-
lowed by incubation for 2 h. 100 ll of buffer was trans-
ferred per well to a 96-well plate. Absorbance (570 nm)
was measured using a Sunrise plate reader (Labtech
International Ltd., Ringmer, UK).
Statistical analysis
Student’s t test was performed using SPSS 15.0 software;
p\ 0.05 was considered significant.
Results
Generation of human stromal cell-derived ECM
surfaces with LOX-dependent cross links
ECM generation was induced in confluent monolayers of
primary human trabecular bone-derived osteoblasts iso-
lated from post-operative human trabecular bone and
human HCA2 dermal fibroblasts. After 10 days
Table 1 Criteria used for scoring different modes of prostate cancer cell migration
Migratory mode Cellular morphology observed during translocation Criteria used to define the predominant
mode of migration
Grouped Epithelioid; as part of a moving cell cluster or participation in frequent
interactions with adjacent cells
[80 % cells display epithelioid
morphology during translocation
Singular, bipolar Mesenchymal; movement as elongated singular cell with defined leading
edge and retraction of trailing uropod
Rounded/bipolar ratio\1.0
Singular, rounded Amoeboid; movement as spheroid without a retracting uropod Rounded/bipolar ratio[1.0
Singular, mixed Equal numbers of cells with mesenchymal and amoeboid morphologies Rounded/bipolar ratio = 1.0
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immunofluorescent staining of type I collagen fibers was
performed on decellularized osteoblast-derived ECM
(Fig. 1a) and decellularized fibroblast-derived ECM
(Fig. 1b). Image analysis revealed that inhibition of colla-
gen crosslinking with the LOX inhibitor BAPN did not
affect the total levels of type I collagen deposition by
human osteoblasts (Fig. 1c) or HCA2 fibroblasts (Fig. 1d)
but induced a significant increase in the curvature ratio of
the collagen fibers in both types of matrices (Fig. 1e, f).
Von Kossa staining of osteoblast-derived ECM indicated
that BAPN treatment does not affect mineralization
(Fig. 1g). These results confirm that human osteoblast-
derived ECM and human fibroblast-derived ECM both
require LOX to maintain their organized structure, thus
providing two physiologically relevant substrata for
studying how tumor-associated Endo180 modulates the
plasticity of prostate cancer cell migration in the presence
and absence of LOX-dependent collagen crosslinking.
Rounded metastatic prostate cancer cell migration is
favored on human bone matrix
Three prostate cancer cell lines were included in the study:
PC3 and VCaP that originate from bone metastatic lesions
located in the lumbar vertebra [40, 41] and DU145 that
originate from a soft tissue metastatic lesion in the parieto-
Fig. 1 LOX inhibition increases type I collagen fiber curvature in
matrices produced by human stromal cells. a, b Immunofluorescent
images of type I collagen fibers produced by primary human
trabecular bone osteoblasts (a) and human HCA2 dermal fibroblasts
(b) in the absence (-BAPN) or presence (?BAPN) of LOX inhibitor
(1 mM), scale bar = 50 lm. c, d Relative levels of total type I
collagen deposited by osteoblasts (c) and fibroblasts (d) in the
absence (–) or presence of BAPN (0.01–1 mM) (average ± s.d. of
integrated fluorescent intensity of immunostaining per lm2). e,
f Collagen fiber curvature ratio in the matrices deposited by
osteoblasts (e) and fibroblasts (f) in the absence (–) or presence of
BAPN (0.01–1 mM); 20 collagen fibers measured for each condition
in duplicate. e, f Average ± s.d. values for three individual exper-
iments, within which each experimental condition in duplicate, are
shown; significant differences compared to control (no BAPN
treatment) are indicated (*p\ 0.05, **p\ 0.001 and
***p\ 0.0003). g Von Kossa staining of osteoblast derived ECM
generated in the absence (-BAPN) or presence (?BAPN) of LOX
inhibitor (1 mM), scale bar = 50 lm
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occipital fissure of the cerebrum [42]. Time-lapse video
microscopywas used to compare theirmigratory behavior on
standard tissue culture plastic, commercial type I collagen,
fibroblast-derived ECM and osteoblast-derived ECM, as
seen in the videos (Online Resources 1–12) and corre-
sponding video stills (Fig. 2a). All movies were scrutinized
and the observed mode of migration for each cell in the field
of view was scored according to the criteria presented in
Table 1. In the case of the two epithelioid-like cell lines,
VCaP and DU145, the proportion of cells engaged in
grouped and singular modes of cell migration were
calculated (Fig. 2b, c). Under all other experimental condi-
tions[20 % of cells adopted a singular migratory mode,
whichwas considered sufficient for the rounded/bipolar ratio
of cell migratory mode to be calculated (Fig. 2d).
PC3 and VCaP cells, but not DU145 cells, transitioned
towards singular and bipolar modes of migration on collagen
in comparison to tissue culture plastic (Fig. 2b–d). On the
other hand, fibroblast-derived ECM supported singular
mixed bipolar/rounded modes of migration for PC3 cells, a
singular rounded mode of migration for VCaP cells and a
singular bipolar mode migration for DU145 cells (Fig. 2d).
Fig. 2 Human stromal cell-
derived surfaces promote
plasticity of movement in
metastatic prostate cancer cells.
a Stills extracted from Videos
1–12 in Online Resources 1–12
of PC3, VCaP and DU145
migrating on tissue culture
plastic, commercial rat-tail type
I collagen and native ECM
generated by human HCA2
dermal fibroblasts (fibroblast
ECM) and primary human
trabecular bone osteoblasts
(osteoblast ECM); scale
bar = 50 lm. b, c The
percentages of VCaP cells
(b) and DU145 cells
(c) participating in grouped and
singular modes of cell migration
on the four substrata. d The
rounded:bipolar ratios for
singular PC3, VCaP and DU145
cells migrating on the four
substrata; significant increases
compared to type I collagen
(*p\ 0.01) and fibroblast ECM
(?p\ 0.01) are indicated. b–
d Average ± s.d. values for
three individual experiments,
within which each experimental
condition was tested in
quadruplicate, are shown
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Moreover, for all three cell-types the predominant mode of
migration on osteoblast-derived ECM was singular and
rounded (Fig. 2d). The rounded migration of PC3 and
DU145 cells on osteoblast-derivedECMwas associatedwith
a high velocity (Fig. 3a), a decreased adhesion (Fig. 3b) and
decreased proliferation (Fig. 3c) when compared to the same
parameters on plastic. In contrast, the rounded migratory
mode of VCaP cells that predominated on both fibroblast-
derived and osteoblast-derived ECM was associated with a
low velocity (Fig. 3a), no change in adhesion (Fig. 3b) and
decreased proliferation (Fig. 3c) when compared to plastic.
These data confirm that metastatic prostate cancer cells
display plasticity in their mode of migration on human
stromal cell-derived ECM.
Endo180 is upregulated in metastatic prostate
cancer cells in contact with human ECM
Flow cytometry analysis using three anti-human Endo180
monoclonal antibodies (A5/158, E1/183, 39.10) confirmed
that the receptor is expressed in PC3, VCaP and DU145 cells
(Fig. 4a). The differential Endo180 staining profiles of the
three antibodies may reflect differences in their epitope
engagement and/or masking by ligand binding and/or the
open-closed conformational state of the receptor, as a
molecular mechanism postulated in our two recent studies
[17, 18]. Immunofluorescent staining analysis confirmed that
Endo180 levels were significantly increased in DU145 cells,
parental PC3 cells and PC3 cells that overexpress Endo180
(PC3-Endo180) cultured on human osteoblast-derived ECM
and fibroblast-derived ECM (Fig. 4b, c). Endo180 appeared
to cluster in ‘hot-spots’ in cells with a rounded phenotype
(Fig. 4b). Immunoblot analysis and densitometry confirmed
that Endo180was also upregulated inVCaP cells cultured for
6-24 h on human osteoblast-derived ECM (up to 4-fold) and
fibroblast-derived ECM (up to 9-fold) (Fig. 4d, e);
immunoblotting results were similar for PC3 and DU145
cells (Supplementary Data Figure S1). The decrease in
Endo180 levels at 48 h could be due to the depletion of
factors that promote Endo180 expression in the bone
microenvironment, such as transforming growth factor-beta-
1 (TGFb1). These findings are in accordance with results
obtained using co-cultures of human trabecular bone-
derived osteoblasts and DU145 or PC3 cells [4], Endo180
immunostaining of tumor cell foci in MBD [4] and its raised
levels in the serum of patients with osseous and/or visceral
metastases [31].
Endo180 is required for rounded prostate cancer
cell migration on human stromal ECM surfaces
To test the hypothesis that Endo180 contributes to the
plasticity of prostate cancer cell migration, PC3 cells were
transfected with a scrambled control shRNA vector (PC3-
shSCN) or targeted Endo180 shRNA vector (PC3-shEn-
do180) (Fig. 5a), which contained a previously validated
Fig. 3 The migration, adhesion and proliferation rates of metastatic
prostate cancer cells are differentially modulated on human stromal
cell-derived ECM surfaces. a–c The migratory velocities (lm/h) over
a 24 h time-frame (a), adhesion levels at 1 h (b) proliferation rates at
48 h (c) of PC3, VCaP and DU145 cells cultured on tissue culture
plastic (plastic), rat-tail type I collagen (type I collagen), human
HCA2 fibroblast-derived ECM (fibroblast ECM) and human trabec-
ular bone osteoblast-derived ECM (osteoblast ECM). a–c Aver-
age ± s.d. values for three individual experiments, within which each
experimental condition was tested in quadruplicate, are shown.
Significant increases (*p\ 0.05) and decreases (?p\ 0.05) com-
pared to plastic are indicated
Clin Exp Metastasis (2016) 33:151–165 157
123
siRNA oligonucleotide sequence [17, 19, 23, 24, 26, 27, 30]
and was highly effective at silencing Endo180 (Fig. 5b, c).
PC3-shSCN cells displayed a predominantly bipolar
migratory mode on fibroblast-derived ECM and a pre-
dominantly rounded migratory mode on osteoblast-derived
ECM, as seen in time-lapse videos (Online Resources 13
and 14) and corresponding frames (Fig. 5d, e). PC3-
shEndo180 cells displayed a significant transition towards a
bipolar morphology on both fibroblast-derived ECM and
osteoblast-derived ECM, as seen in videos (Online
Resources 16 and 17) and corresponding frames (Fig. 5d,
e). Moreover, the rounded-to-bipolar transition that resul-
ted from Endo180 silencing was accompanied by a dra-
matic reduction in cell velocity (Fig. 5f) associated with
Fig. 4 Endo180 is upregulated in metastatic prostate cancer cells
cultured on human stromal cell-derived ECM surfaces. a Flow
cytometry analysis of PC3, VCaP and DU145 cells using three anti-
human Endo180 monoclonal antibodies (A5/158, E1/183, 39.10).
b Immunofluorescent staining of Endo180 (A5/158 mAb) in PC3-
Endo180 cells cultured on plastic and ECM generated by primary
human trabecular bone osteoblasts (osteoblast ECM); scale
bar = 50 lm. c Relative levels of Endo180 expression (integrated
fluorescent intensity; A5/158 mAb immunostaining) in PC3, PC3-
Endo180 and DU145 cells cultured on tissue culture plastic (plastic)
and ECM generated by primary human trabecular bone osteoblasts
(osteoblast ECM) and human HCA2 dermal fibroblasts (fibroblast
ECM); average ± s.d. values for three individual experiments, within
which each experimental condition was tested in quadruplicate, are
shown; significant differences compared to plastic are indicated
(*p\ 0.05). d Immunoblot shows Endo180 expression (A5/158
mAb) in VCaP cells cultured on plastic, rat-tail type I collagen
(collagen), osteoblast ECM and fibroblast ECM for 6, 24 and 48 h
(GAPDH = loading control). e Relative levels of Endo180 expres-
sion in (d) quantified using densitometry (n = 1)
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defective cell detachment from fibroblast-derived ECM
and osteoblast-derived ECM, as seen in videos (Online
Resources 15 and 16). The adhesion (Fig. 5g) and
proliferation (Fig. 5h) rates of PC3-shSCN and PC3-
shEndo180 cells on all substrata were similar to those for
parental PC3 cells (Fig. 3b, c). These data confirm that
Fig. 5 Silencing Endo180 inhibits metastatic prostate cancer cell
migration on human stromal-derived ECM surfaces. a Brightfield and
immunofluorescent images of PC3 cells transfected with control
shRNA vector containing a targeting Endo180 oligonucleotide
sequence (PC3-shEndo180); scale bar = 100 lm. b, c Immunoblot
analysis (A5/158 mAb) (b) and corresponding denistometric analysis
(c) confirming decreased Endo180 expression in PC3-shEndo180
cells compared to control PC3 cells transfected with a vector
containing a non-targeting (scrambled) Endo180 oligonucleotide
sequence (PC3-shSCN) (a-tubulin = loading control). d Stills
extracted from Videos 13–16 in Online Resources 13–16 of PC3-
shSCN and PC3-shEndo180 cells migrating on native ECM generated
by human HCA2 dermal fibroblasts (fibroblast ECM) and primary
human trabecular bone osteoblasts (osteoblast ECM); scale
bar = 50 lm. e The rounded:bipolar ratios of PC3-shSCN and
PC3-shEndo180 cells migrating on fibroblast ECM and osteoblast
ECM. f Migration velocities (lm/h) of PC3-shSCN and PC3-
shEndo180 cells migrating for 24 h on human fibroblast-derived
ECM and human osteoblast-derived ECM; significant decreases in the
velocity of PC3-shEndo180 cells compared to pc3-shSCN cells are
indicated (?p\ 0.01). g, f The adhesion levels at 1 h (g) and
proliferation rates at 48 h (h) of PC3-shSCN and PC3-shEndo180
cells are shown; significant increases (*p\ 0.05) and decreases
(?p\ 0.05) compared to plastic are indicated. e–h Average ± s.d.
values for three individual experiments, within which each experi-
mental condition was tested in quadruplicate, are shown
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Endo180 promotes rounded prostate cancer cell migration
on human stromal-cell derived ECM surfaces.
Endo180 cooperates with fibroblast-derived LOX
to promote metastatic prostate cancer cell migration
Given that prostate epithelial cell-associated Endo180
cooperates with AGE-mediated crosslinking of the base-
ment membrane to promote invasiveness [18], we tested
the hypothesis that Endo180-dependent metastatic prostate
cancer cell migration is promoted by LOX-dependent
crosslinking in the stromal ECM associated with bone and
visceral tissue. The migratory velocity of parental PC3 and
PC3-Endo180 cells, but not DU145 cells, was decreased on
ECM generated by confluent monolayers of human HCA2
fibroblasts treated with the LOX inhibitor BAPN
(0.01–1.0 mM) when compared to their migratory velocity
on ECM generated by untreated HCA2 fibroblasts
(Fig. 6a). The decrease in PC3 and PC3-Endo180 cell
migration on ECM generated by HCA2 fibroblasts treated
with BAPN was correlated with an increase in Endo180
expression (Fig. 6b). However, no difference in the
migratory velocity of PC3 cells (Fig. 6c), VCaP cells
(Fig. 6d) and DU145 cells (Fig. 6e) was observed on ECM
generated by untreated primary human trabecular bone-
derived osteoblasts compared to osteoblasts treated with
Fig. 6 Endo180 requires LOX-dependent ECM crosslinking of
human fibroblast-derived ECM surfaces to promote metastatic
prostate cancer cell migration. a Migration velocities (lm/h) of
DU145, PC3 and PC3-Endo180 cells for a duration of 24 h on ECM
derived from human HCA2 dermal fibroblasts in the absence (-) or
presence of the LOX inhibitor BAPN (0.01–1 mM); significant
increases (*p\ 0.05) and decreases (?p\ 0.05) compared to cells
migrating on control ECM generated by fibroblasts in the absence of
BAPN (-) are indicated. b Relative levels of Endo180 expression
(integrated fluorescent intensity; A5/158 mAb immunostaining) in
DU145, PC3 and PC3-Endo180 cells cultured for 24 h on ECM
derived from human HCA2 dermal fibroblasts in the absence (-) or
presence of BAPN (0.01–1 mM); significant increases compared to
corresponding each corresponding cell line cultured on control
fibroblast ECM (-) are indicated (*p\ 0.05). c–e Migration veloc-
ities (lm/h) of PC3 (c), VCaP (d) and DU145 (e) cells migrating for
24 h on ECM derived from primary human trabecular bone
osteoblasts in the absence (-) or presence of the LOX inhibitor
BAPN (1 mM); no significant differences were observed. a–e Aver-
age ± s.d. values for three individual experiments, within which each
experimental condition was tested in quadruplicate, are shown.
f Schematic diagram that summarizes the findings of this study and
their potential therapeutic implications in the context of bone and
visceral metastasis. Metastatic prostate cancer cells adopt a rounded
mode of cell migration on fibroblast-derived and osteoblast-derived
ECM that is associated with increased Endo180 expression. Silencing
Endo180 (-Endo180) prevents the translocation of prostate cancer
cells on fibroblast-derived ECM and osteoblast-derived ECM due to a
detachment defect and the potential loss of Endo180-dependent
mechanotransduction. Inhibition of fibroblast-derived LOX activity
(-LOX) uncouples Endo180 from its pro-migratory capacity, possibly
via loss of its capacity for mechanotransduction in the more compliant
non-crosslinked ECM. In contrast the inhibition of osteoblast-derived
LOX does not affect prostate cancer cell migration, potentially due to
the non-crosslinked mineralized ECM being stiff enough to promote
Endo180-dependent mechanotransduction and migration. This model
supports the use of anti-LOX therapy for metastasis in visceral tissue
and anti-Endo180 therapy for metastasis in bone
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1.0 mM BAPN (Fig. 6c). These data suggest that meta-
static prostate cancer cell migration involves cooperation
between tumor-associated Endo180 and LOX-dependent
crosslinking in human fibroblast-derived ECM but not
osteoblast-derived ECM.
Discussion
In this paper we explored the role of two emerging anti-
metastatic targets involved in collagen matrix homeostasis,
Endo180 and LOX, in directing the plasticity of metastatic
prostate cancer cells on human ECM surfaces. The in vitro
model developed for this purpose involved the introduction
of PC3 and VCaP cells originating from metastatic bone
lesions [40, 41] and DU145 cells originating from a
metastatic lesion in the brain [42] onto human osteoblast-
derived and fibroblast-derived ECM. VCaP cells adopted a
singular and rounded mode of cell migration, and DU145
cells a singular and bipolar mode of cell migration, on
fibroblast-derived ECM. This contrasted with their grouped
migratory mode under standard culture conditions on tissue
culture plastic or a low concentration of non-polymerized
reconstituted type I collagen. Moreover, all three prostate
cancer cell lines adopted a singular and rounded mode of
cell migration on osteoblast-derived ECM (Table 2). These
changes in prostate cancer cell migration on human stromal
cell-derived ECM closely recapitulate the ‘amoeboid-like’
mode of migration of tumor cells observed within 3-D
lattices formed by high concentrations of polymerized
reconstituted type I collagen [11, 43, 44]. These findings
suggest that the therapeutic strategies uncovered in these
earlier studies may be useful in blocking rounded tumor
cell migration and diseemination in MBD and other types
of bone cancer.
The intracellular mechanisms of rounded tumor cell
migration delineated so far have been centered upon the
suppressor and activator signals that regulate RhoA-ROCK
and myosin light chain-2 (MLC2)-dependent actino-
myosin-based contractility, cytoskeletal remodeling and
dynamic cell adhesion events. For example, it has been
demonstrated that rounded cell movement can be reversed
by Smurf-1, a E3 ubiquitin ligase that targets RhoA for
degradation, and PDK1, which antagonizes the RhoE-de-
pendent activation of ROCK [45, 46]. Rounded cell
migration is also driven by aberrant activation of RhoA
following loss of p53 and p27, the suppression of Rac1 and
SOX2, or the expression of EphA2 [43, 47–52]. The
interaction between RhoC and FMNL2, Cdc42 and its
regulators (DOCK10, RasGRF2) and effectors (N-WASP,
PAK2), also promotes rounded cell migration [44, 53–56];
whereas the dephosphorylation of stathmin (a microtubule
destabilizing protein), loss of cofilin or depletion of paxillin
can block rounded cell migration [57–59].
In this study we have pinpointed the collagen receptor
Endo180 as a novel modulator of rounded tumor cell
migration in the context of the bone (osteoblast-derived
ECM) and visceral tissue (fibroblast-derived ECM)
microenvironments. This novel pro-migratory mechanism
is consolidated by the upregulation of Endo180 expression
by up to*20-fold in PC3 cells,*9-fold in VCaP cells and
*7-fold in DU145 cells on osteoblast-derived ECM
compared to control substrata. The possible intracellular
cues that can direct this Endo180-associated tumor cell
Table 2 Migratory mode,
velocity, adhesion and
proliferation rates of human
prostate cancer cell lines on
human fibroblast and osteoblast-
derived matrices
Substratum PC3 cells VCaP cells DU145 cells
Tissue culture plastic Singular, bipolar Grouped, epithelioid Grouped, epithelioid
Commercial type I collagen Singular, Bipolar
* Velocity
, Adhesion
, Proliferation
Singular, bipolar
, Velocity
, Adhesion
, Proliferation
Grouped, epithelioid
, Velocity
+ Adhesion
+ Proliferation
Fibroblast ECM Singular, mixed
, Velocity
+ Adhesion
, Proliferation
Singular, rounded
+ Velocity
, Adhesion
+ Proliferation
singular, bipolar
* Velocity
, Adhesion
+ Proliferation
Osteoblast ECM Singular, rounded
* Velocity
+ Adhesion
+ Proliferation
Singular, rounded
+ Velocity
, Adhesion
+ Proliferation
Singular, rounded
* Velocity
+ Adhesion
+ Proliferation
Definition of migratory modes: grouped ([80 % of cells migrate as part of an epithelioid cluster); bipolar
(rounded/bipolar ratio\1.0); rounded (rounded/bipolar ratio[1.0); mixed (rounded/bipolar ratio = 1.0).
All changes shown are in comparison to plastic
ECM extracellular matrix
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plasticity include Cdc42 and Rac1 and the Rho-ROCK-
MLC2 pathway, which are activated by the spatiotemporal
localization of the Endo180 receptor to the plasma mem-
brane or constitutively recycling endosomes [18, 19, 26].
Interestingly two key Endo180 interaction partners, CD147
and urokinase-type plasminogen activator receptor (uPAR)
[17, 26], have been identified as regulators of rounded cell
migration [60, 61]. CD147-annexin II complex acts as a
molecular switch that directs rounded-to-bipolar transitions
during cell migration. It is feasible that Endo180-CD147
complex [17] also plays a modulatory role in tumor cell
plasticity on human stromal cell-derived ECM. In this
respect we hypothesize that Endo180-CD147 complex
disruption can promote rounded tumor cell migration and
Endo180-CD147 complex formation can uncouple
Endo180 and the intracellular machinery that drives roun-
ded tumor cell migration. It is also possible that the inte-
grin-dependent actomyosin contractile signals generated at
the pseudo-uropod-like structure at the rear of spheroidal
cells during rounded cell migration [14] involves the spa-
tiotemporal activation of Rho-ROCK-MLC2-based con-
tractile signals by Endo180-containing endosomes. This
prediction is supported by the fact that de-adhesion of the
uropod at the rear of MG63 osteosarcoma cells requires the
Endo180-Rho-ROCK-MLC2 signalling axis [19]. It will
also be interesting to consider if the strong Endo180
clusters in PC3-Endo180 cells on osteoblast-derived ECM
contribute to their rounded mode of migration.
The requirement of LOX-dependent ECM crosslinking
and stiffness for Endo180-dependent tumor cell migration
is aligned with the finding that non-enzymatic crosslinking
of basement membrane matrix coupled with Endo180-de-
pendent mechanotransduction triggers epithelial cell inva-
siveness [18]. When considering the design of Endo180
based anti-metastatic therapies it will be important to fully
explore the relative contributions of the two functional
C-type lectin domains (CTLDs) in the receptor, CTLD2
and CTLD4, to the migratory behavior of metastatic
prostate cancer cells in the context of human ECM lattices
that have different levels of stiffness. Our findings indicate
that where the ECM is more compliant Endo180 and
CD147 form a molecular complex that involves CTLD4
and suppresses epithelial cell invasiveness [17]. This sug-
gests that in compliant tissue it would not be desirable to
target CTLD4. On the flipside, blockade of CTLD2-de-
pendent mechanotransduction, which can inhibit the
epithelial cell invasiveness induced by non-enzymatic
crosslinking and increased stiffness of the basement
membrane [18], could be used to prevent rounded tumor
cell migration in stiff visceral tissue and bone.
In contrast to the finding that Endo180 is uncoupled
from its ability to promote tumor cell migration on com-
pliant (non-crosslinked) fibroblast-derived ECM, no
differences were observed in the migration of tumor cells
on non-crosslinked versus crosslinked osteoblast-derived
ECM. Although our findings suggest that osteoblast-
derived LOX does not affect metastatic prostate cancer cell
migration, tumor-derived LOX participates in the pro-
gression of osteolytic bone metastasis in breast cancer [38].
In the current study we did not consider the cooperative
roles of tumor-derived LOX and Endo180 in driving the
plasticity of tumor cell movement on human fibroblast-
derived and osteoblast-derived ECM surfaces. Considera-
tion of this possibility together with the evaluation of
Endo180 and LOX as targets in pre-clinical models of
osteolytic bone tumors induced by PC3 and DU145 cells
[62–64] and predominantly osteosclerotic tumors induced
by VCaP cells [65] will be prioritised in our future work.
The finding that LOX-dependent crosslinking of human
fibroblast-derived ECM is required to promote tumor cell
migration, indicates that anti-Endo180 and/or anti-LOX
therapy is a feasible therapeutic option for the treatment of
visceral tumors surrounded by a stiffened stroma (Fig. 6f).
The findings of this study provide new insight into the
consequences of Endo180 upregulation on prostate tumor
cells in contact with osteoblasts [4], positive Endo180
immunostaining of tumor cell foci in metastatic bone lesions
[4] and raised levels of soluble Endo180 in the serum of
patients with osseous and/or visceral metastases [31]. The
heterotypic interaction of osteoblasts with prostate cancer
cells was previously shown to suppress Endo180 expression
in the osteoblasts resulting in decreased mineralized colla-
gen production [4]. Here we have demonstrated that osteo-
blast-derived ECM increases Endo180 expression in tumor
cells to drive their transition to a roundedmode of migration.
Therapeutic strategies that can suppress Endo180 function in
metastatic disease (Fig. 6f), combinedwith the development
of Endo180-targeted diagnostics, could provide the oppor-
tunity tomake amajor advance in the personalized treatment
ofmenwith Endo180-positive prostate cancerwho are at risk
of, or have progressed towards, the development of
Endo180-driven bone metastasis [17, 18].
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